Last reviewed · How we verify

Anesthesia (Lidocaine 15%)

Lumbini Medical College · FDA-approved active Small molecule

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

Lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses to produce local anesthesia. Used for Topical local anesthesia for minor surgical procedures and pain relief.

At a glance

Generic nameAnesthesia (Lidocaine 15%)
Also known asNummit
SponsorLumbini Medical College
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Lidocaine is a local anesthetic that works by inhibiting sodium influx through sodium-selective channels in the nerve cell membrane, thereby preventing depolarization and blocking the generation and propagation of action potentials. At a 15% concentration, it is formulated for topical application to provide rapid onset of anesthesia at the site of application. This mechanism allows it to numb tissue locally without systemic effects when applied appropriately.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: